Synthesis of Substituted Tri- and Tetracyclic Compounds Bearing a Pyridazine Core and their Biological Evaluation as Antimycobacterial Agents

Archiv der Pharmazie

Volumn 333, Issue 7, 2000, Pages 231-240

  Heinisch, Gottfried ^a   Matuszczak, Barbara ^a   Planitzer, Karin ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Antimycobacterial agents; Antituberculotic agents; Naphtho 2,1 b pyridazino 4,3 f 1,4 oxazepin 12(13h) ones; Pyridazino 3,4 b 1,5 benzoxazepin 5(6h) ones

Indexed keywords

ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; LIPID; PYRIDAZINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIUM TUBERCULOSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; HETEROCYCLIC COMPOUNDS; LIPIDS; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; PYRIDAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034221121     PISSN: 03656233     EISSN: None     Source Type: Journal    
DOI: 10.1002/1521-4184(20007)333:7<231::AID-ARDP231>3.0.CO;2-1     Document Type: Article

References (25)

1. For part 90 see: G. Heinisch, E. Huber, B. Matuszczak, Heterocycles, 1999, 51, 1625-1630.
2. a) T.M. Shinnick (ed.), Tuberculosis, Springer, 1996;
3. b) N.E. Billo, Global Aspects of Tuberculosis, in: Mycobacteria II Chemotherapy (eds. P.R.J. Gangadharam, P.A. Jenkins), Chapman & Hall, 1998, 1-14;
4. c) W.R. Baker, L.A. Mitscher, T.M. Arain, R. Shawar, C.K. Stover, Recent Advances in the Chemistry and Biology of Antimycobacterial Agents; in: Annual Reports in Medicinal Chemistry (ed. J.A. Bristol), 1996, 31, 161-170 and literature cited therein.
5. a) P.T. Davidson, H.Q. Le, Drugs 1992, 43, 651-673;
6. b) G.L. Mandell, W. A. Petri, Jr., Antimicrobial Agents: Drugs used in the Chemotherapy of Tuberculosis, Mycobacterium avium Complex Disease, and Leprosy, in: Goodman and Gilman's The Pharmacological Basis of Therapeutics (eds. J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A. Goodman Gilman), McGraw-Hill, New York, 1995, 1155-1174;
7. c) A.K. Dutt, J.B. Mehta, Chemotherapy of Tuberculosis in Developed Countries, in: Mycobacteria II: Chemotherapy (eds. P.R.J. Gangadharam, P.A. Jenkins), Chapman & Hall, 1997, 131-160.
8. For a review see: P.R.J. Gangadharam, New Drugs and Strategies for Chemotherapy of Tuberculosis, in: Mycobacteria II: Chemotherapy (eds. P.R.J. Gangadharam, P.A. Jenkins), Chapman & Hall, 1997, 335-378. It should be noted that in this article several of the chemical structures are not correct.
9. B. Cavalleri, M. Turconi, G. Tamborini, E. Occelli, G. Cietto, R. Pallanza, R. Scotti, M. Berti, G. Romanó, F. Parenti, J. Med. Chem. 1990, 33, 1470-1476.
10. J.R. Peterson, J.K. Zjawiony, S. Liu, C.D. Hufford, A.M. Clark, R.D. Rogers, J. Med. Chem. 1992, 35, 4069-4077.
11. a) T.E. Renau, J.P. Sanchez, J.W. Gage, J.A. Dever, M.A. Shapiro, S.J. Gracheck, J.M. Domagala, J. Med. Chem. 1996, 39, 729-735;
12. b) T.E. Renau, J.P. Sanchez, M.A. Shapiro, J.A. Dever, S.J. Gracheck, J.M. Domagala, J. Med. Chem. 1995, 38, 2974-2977.
13. a) S.J. Brickner, D.K. Hutchinson, M.R. Barbachyn, P.R. Manninen, D.A. Ulanowicz, S.A. Garmon, K.C. Grega, S.K. Hendges, D.S. Toops, C.W. Ford, G.E. Zurenko, J. Med. Chem. 1996, 39, 673-679;
14. b) M.R. Barbachyn, D.K. Hutchinson, S.J. Brickner, M.H. Cynamon, J.O. Kilburn, S.P. Klemens, S.E. Glickman, K.C. Grega, S.K. Hendges, D.S. Toops, C.W. Ford, G.E. Zurenko, J. Med. Chem. 1996, 39, 680-685.
15. a) G.A. Wächter, M.C. Davis, A.R. Martin, S.G. Franzblau, J. Med. Chem. 1998, 41, 2436-2438;
16. b) M.H. Cynamon, S.P. Klemens, J. Med. Chem. 1992, 35, 1212-1215;
17. c) K.E. Bergmann, M.H. Cynamon, J.T. Welch, J. Med. Chem. 1996, 39, 3394-3400;
18. d) M.H. Cynamon, R. Gimi, F. Gyenes, C.A. Sharpe, K.E. Bergmann, H.J. Han, L.B. Gregor, R. Rapolu, G. Luciano, J.T. Welch, J. Med. Chem. 1995, 38, 3902-3907.
19. N. Karah, N. Terzioglu, A. Gürsoy, Arzneim.-Forsch./Drug Res. 1998, 48, 758-763.
20. W. Meindl, Arch. Pharm. (Weinheim) 1989, 322, 493-497 and literature cited therein.
21. B. Barth, M. Dierich, G. Heinisch, V. Jenny, B. Matuszczak, K. Mereiter, R. Planer, I. Schöpf, H. Stoiber, T. Traugott, P. v. Aufschnaiter, Antiviral Chem. Chemother. 1996, 7, 300-312.
22. W. Ried, T.A. Eichhorn, Arch. Pharm. (Weinheim) 1988, 321, 527-532.
23. The biological tests were performed at the NIAID [National Institute of Allergy and Infectious Diseases; Southern Research Institute (TAACF), USA.
24. Calculation was performed using the program: Pallas Chemical Software Series.
25. The test system used here is a screening method for detecting an active compound (with inhibition > 90%). Therefore, the experiment is carried out only once.